Adaptive Biotechnologies

Adaptive Biotechnologies was founded on the understanding that the adaptive immune system is a remarkable natural diagnostic and therapeutic tool. Our customers, including researchers, clinicians, and pharmaceutical companies, face the immense challenge of understanding and combating complex diseases like cancer, autoimmune disorders, and infectious diseases. The inability to fully decode the intricacies of the adaptive immune system has historically limited the medical community's ability to leverage its full potential. That's why we developed a proprietary immune medicine platform capable of revealing and translating the massive genetics of the adaptive immune system with unprecedented scale, precision, and speed.

Our customers in life sciences research utilize our platform to make groundbreaking discoveries. For those in clinical diagnostics, we provide tools like our FDA-cleared clonoSEQ® assay, which is instrumental in detecting and monitoring minimal residual disease (MRD) in various blood cancers, including multiple myeloma, B-cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). This empowers healthcare providers to make more informed treatment decisions, predict patient outcomes, assess therapy response over time, and detect potential relapse earlier. Furthermore, our platform fuels drug discovery by identifying novel therapeutic targets and understanding immune responses to new treatments. We partner with biopharmaceutical companies to inform drug development, aiming to develop and commercialize immune-driven clinical products tailored to each individual patient. The core challenge our customers face is the complexity and diversity of the immune system; our technology provides the means to navigate this complexity, turning vast biological data into actionable insights that can ultimately transform patient care and lead to a future where diseases are better understood, diagnosed, and treated.